Job vacancy in Zydus lifesciences walk-in on 18th may for freshers and Experience for production/ Packing/ warehouse/ QA/ QC
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. In 1995, the Patel and Modi families split; the Modi family’s share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family’s holding company. Cadila Healthcare had its initial public offering in February 2000 and listed on the BSE. In 2003, the company merged another Indian pharmaceutical company called German Remedies into itself.[10] On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda. In 2014, Cadila Healthcare launched the world’s first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator’s price. Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in the treatment of Diabetic Dyslipidemia under brand name “Lipaglyn”. SoviHep is the first sofosbuvir brand launched in India by Zydus in the year 2015. In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth. In 2020, Zydus Cadila’s drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients. In 2022, Cadila Healthcare Ltd was renamed as Zydus Lifesciences Ltd.
More about company
Vacancy details –
Department – Fix term employee & Apprentice
Qualification – ITI/ Diploma engeneering/ Diploma pharmacy/ B tech/ BE/ BA/ B com
Experience – 0 to 4 years
Salary – Not disclosed by recruiter
Similar job’s
Job vacancy in Ipca laboratories walk-in drive on 19th May 2024
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. In 1995, the Patel and Modi families split; the Modi family’s share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family’s holding company. Cadila Healthcare had its initial public offering in February 2000 and listed on the BSE. In 2003, the company merged another Indian pharmaceutical company called German Remedies into itself.[10] On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda. In 2014, Cadila Healthcare launched the world’s first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator’s price. Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in the treatment of Diabetic Dyslipidemia under brand name “Lipaglyn”. SoviHep is the first sofosbuvir brand launched in India by Zydus in the year 2015. In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth. In 2020, Zydus Cadila’s drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients. In 2022, Cadila Healthcare Ltd was renamed as Zydus Lifesciences Ltd. From twenty-five pharmaceutical production operations in India and Zydus Cadila develops and manufactures an extensive range of pharmaceuticals as well as diagnostics, herbal products, skincare products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep). The company makes active pharmaceutical ingredients at four sites in India, Ankleshwar plants, Vadodara plant, and Ahmedabad plant.
Zydus Cadila’s major shareholder remains the Patel family. Pankaj Patel (born 1953), son of the founder, is the chairman of the company. In 2004, Pankaj Patel was included in Forbes’ annual list of India’s richest people. As of 2020, Forbes estimates Patel’s net worth at US$3.9 billion, making him India’s 46th richest person.
Important details –
Location – Chennai
Selection process – The selection will be on the basis of interview
Mode of interview – Face to face
Interview rounds of interview – HR
Walk-in interview details –
Date- 18th may 2024
Time – 09:00 Am to 03:00 Pm
Venue – zydus lifesciences limited ( formerly known as cadila healthcare limited) plot no 1A/1 & 2, PHARMEZ-SEZ , sarkhej – Bavla N.H.8A , at matoda , Tal Sanand , Dist Ahemdabad, Gujrat – 382213
Inviting candidates for walk-in interview for SEZ 1 manufacturing unit , Ahemdabad on 18th may 24 – Saturday from 9:00 Am to 3:00 Pm